Pipeline· May 26, 2026 · 8 min readCagriSema (cagrilintide/semaglutide): pre-approval evidence, REDEFINE trial results, and what access teams should expectPipeline evidence review of Novo Nordisk's CagriSema, the first GLP-1/amylin combination for obesity. REDEFINE 1, 2, and 4 trial data,...By Ran Chen#GLP-1#Amylin Analog#Obesity
